Overexpression of eIF5A-2 is an adverse prognostic marker of survival in stage I non-small cell lung cancer patients

International Journal of Cancer

Volumn 129, Issue 1, 2011, Pages 143-150

  He, Li Ru ^a   Zhao, Hong Yun ^a   Li, Bin Kui ^a   Liu, Yan Hui ^b   Liu, Meng Zhong ^a   Guan, Xin Yuan ^a   Bian, Xiu Wu ^c   Zeng, Yi Xin ^a   Xie, Dan ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

^c THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

amplification; eIF5A 2; immunohistochemistry; non small cell lung carcinoma; prognosis

Indexed keywords

EUKARYOTIC INITIATION FACTOR 5A2; INITIATION FACTOR; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CELL PROLIFERATION; CHROMOSOME 3Q; CONTROLLED STUDY; EIF5A 2 GENE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; LUNG PARENCHYMA; MAJOR CLINICAL STUDY; MALE; ONCOGENE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; UPREGULATION;

CARCINOMA, NON-SMALL-CELL LUNG; COHORT STUDIES; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; LUNG NEOPLASMS; MALE; MIDDLE AGED; PEPTIDE INITIATION FACTORS; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 79955446362     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25669     Document Type: Article

References (27)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ,. Cancer statistics, 2008. CA Cancer J Clin 2008; 58: 71-96. (Pubitemid 351521864)
2. Grondin SC, Liptay MJ,. Current concepts in the staging of non-small cell lung cancer. Surg Oncol 2002; 11: 181-90. (Pubitemid 35356567)
3. Hotta K, Matsuo K, Ueoka H, Kiura K, Tabata M, Tanimoto M,. Role of adjuvant chemotherapy in patients with resected non-small-cell lung cancer: reappraisal with a meta-analysis of randomized controlled trials. J Clin Oncol 2004; 22: 3860-7. (Pubitemid 41079866)
4. Tomida S, Koshikawa K, Yatabe Y, Harano T, Ogura N, Mitsudomi T, Some M, Yanagisawa K, Takahashi T, Osada H, Takahashi T,. Gene expression-based, individualized outcome prediction for surgically treated lung cancer patients. Oncogene 2004; 23: 5360-70. (Pubitemid 39005811)
5. Sham JS, Tang TC, Fang Y, Sun L, Qin LX, Wu QL, Xie D, Guan XY,. Recurrent chromosome alterations in primary ovarian carcinoma in Chinese women. Cancer Genet Cytogenet 2002; 133: 39-44. (Pubitemid 34224874)
6. Kettunen E, el-Rifai W, Bjorkqvist AM, Wolff H, Karjalainen A, Anttila S, Mattson K, Husgafvel-Pursiainen K, Knuutila S,. A broad amplification pattern at 3q in squamous cell lung cancer - a fluorescence in situ hybridization study. Cancer Genet Cytogenet 2000; 117: 66-70. (Pubitemid 30099659)
7. Guan XY, Sham JS, Tang TC, Fang Y, Huo KK, Yang JM,. Isolation of a novel candidate oncogene within a frequently amplified region at 3q26 in ovarian cancer. Cancer Res 2001; 61: 3806-9. (Pubitemid 32694997)
8. Guan XY, Fung JM, Ma NF, Lau SH, Tai LS, Xie D, Zhang Y, Hu L, Wu QL, Fang Y, Sham JS,. Oncogenic role of eIF-5A2 in the development of ovarian cancer. Cancer Res 2004; 64: 4197-200. (Pubitemid 38802423)
9. Yang GF, Xie D, Liu JH, Luo JH, Li LJ, Hua WF, Wu HM, Kung HF, Zeng YX, Guan XY,. Expression and amplification of eIF-5A2 in human epithelial ovarian tumors and overexpression of EIF-5A2 is a new independent predictor of outcome in patients with ovarian carcinoma. Gynecol Oncol 2009; 112: 314-8.
10. Chen W, Luo JH, Hua WF, Zhou FJ, Lin MC, Kung HF, Zeng YX, Guan XY, Xie D,. Overexpression of EIF-5A2 is an independent predictor of outcome in patients of urothelial carcinoma of the bladder treated with radical cystectomy. Cancer Epidemiol Biomarkers Prev 2009; 18: 400-8.
11. Greene FL PD, Fleming ID, eds. AJCC cancer staging manual, 6th ed. New York: Springer, 2002.
12. Sobin L, Wittekind, C,. UICC TNM classification of malignant tumors, 6th ed. New York: Wiley, 2002.
13. Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G, Kallioniemi OP,. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998; 4: 844-7. (Pubitemid 28331029)
14. Xie D, Lau SH, Sham JS, Wu QL, Fang Y, Liang LZ, Che LH, Zeng YX, Guan XY,. Up-regulated expression of cytoplasmic clusterin in human ovarian carcinoma. Cancer 2005; 103: 277-83. (Pubitemid 40129286)
15. Xie D, Ma NF, Pan ZZ, Wu HX, Liu YD, Wu GQ, Kung HF, Guan XY,. Overexpression of EIF-5A2 is associated with metastasis of human colorectal carcinoma. Hum Pathol 2008; 39: 80-6. (Pubitemid 350216163)
16. Luo JH, Hua WF, Rao HL, Liao YJ, Kung HF, Zeng YX, Guan XY, Chen W, Xie D,. Overexpression of EIF-5A2 predicts tumor recurrence and progression in pTa/pT1 urothelial carcinoma of the bladder. Cancer Sci 2009; 100: 896-902.
17. Xie D, Sham JS, Zeng WF, Lin HL, Bi J, Che LH, Hu L, Zeng YX, Guan XY,. Correlation of AIB1 overexpression with advanced clinical stage of human colorectal carcinoma. Hum Pathol 2005; 36: 777-83. (Pubitemid 41112033)
18. Marchet A, Mocellin S, Belluco C, Ambrosi A, DeMarchi F, Mammano E, Digito M, Leon A, D'Arrigo A, Lise M, Nitti D,. Gene expression profile of primary gastric cancer: towards the prediction of lymph node status. Ann Surg Oncol 2007; 14: 1058-64.
19. Clement PM, Henderson CA, Jenkins ZA, Smit-McBride Z, Wolff EC, Hershey JW, Park MH, Johansson HE,. Identification and characterization of eukaryotic initiation factor 5A-2. Eur J Biochem 2003; 270: 4254-63. (Pubitemid 37340343)
20. Clement PM, Johansson HE, Wolff EC, Park MH,. Differential expression of eIF5A-1 and eIF5A-2 in human cancer cells. FEBS J 2006; 273: 1102-14. (Pubitemid 43345032)
21. Li AL, Li HY, Jin BF, Ye QN, Zhou T, Yu XD, Pan X, Man JH, He K, Yu M, Hu MR, Wang J, et al. A novel eIF5A complex functions as a regulator of p53 and p53-dependent apoptosis. J Biol Chem 2004; 279: 49251-8. (Pubitemid 39625810)
22. Clement PM, Hanauske-Abel HM, Wolff EC, Kleinman HK, Park MH,. The antifungal drug ciclopirox inhibits deoxyhypusine and proline hydroxylation, endothelial cell growth and angiogenesis in vitro. Int J Cancer 2002; 100: 491-8.
23. Nishimura K, Murozumi K, Shirahata A, Park MH, Kashiwagi K, Igarashi K,. Independent roles of eIF5A and polyamines in cell proliferation. Biochem J 2005; 385: 779-85. (Pubitemid 40208839)
24. Shi XP, Yin KC, Ahern J, Davis LJ, Stern AM, Waxman L,. Effects of N1-guanyl-1,7-diaminoheptane, an inhibitor of deoxyhypusine synthase, on the growth of tumorigenic cell lines in culture. Biochim Biophys Acta 1996; 1310: 119-26.
25. Tome ME, Fiser SM, Payne CM, Gerner EW,. Excess putrescine accumulation inhibits the formation of modified eukaryotic initiation factor 5A (eIF-5A) and induces apoptosis. Biochem J 1997; 328 (Part 3): 847-54. (Pubitemid 28005785)
26. Stark GR, Debatisse M, Giulotto E, Wahl GM,. Recent progress in understanding mechanisms of mammalian DNA amplification. Cell 1989; 57: 901-8. (Pubitemid 19168370)
27. Park MH,. The post-translational synthesis of a polyamine-derived amino acid, hypusine, in the eukaryotic translation initiation factor 5A (eIF5A). J Biochem 2006; 139: 161-9.